ALZpath Inc.的动态

Alzheimer’s Disease biomarker biology is advancing for the diagnosis, prognosis and treatment monitoring. Plasma p-tau217 appears to standout in head-to-head comparisons with other AD plasma biomarkers. This is another significant and important step in the management of AD. #AD #AlzheimersDisease #pTau217 #plasmabiomarkers

We're excited to partner with the Global Alzheimer's Platform Foundation to accelerate the investigation of biomarkers of Alzheimer's disease and related dementias (ADRD) ?? ?? Our collaboration grants early access to Bio-Hermes-001 data, supporting efforts to improve diagnosis, prognosis, and treatments. “Large scale biomarker data, in particular blood biomarkers, from leading diagnostic and molecular assay companies, as collected and curated by Bio-Hermes-001 will enable validation and discovery of novel biomarkers of age-related diseases that reduces barriers to access to timely diagnosis for everyone.“ Mahdi Moqri, founding Co-Director of the Consortium. With large-scale biomarker insights, including diverse community representation, this partnership has the potential to drive significant progress in age-related neurodegenerative disease research. ?? Learn more in this press release: https://lnkd.in/eiiTRsBf About the Global Alzheimer’s Platform Foundation (GAP): The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify biomarkers of Parkinson’s disease well in advance of symptoms appearing. The initiative could lead to new diagnostic tools and ways of slowing or stopping the condition’s progression. Parkinson’s disease (PD) is the fastest-growing neurological disorder in the world, affecting around 10 million people globally. While therapies such as medications, surgery and rehabilitation can reduce the symptoms of the condition, there is no cure. As with other chronic diseases that worsen over time, the earlier PD is diagnosed, the earlier it can be treated, ideally slowing its progression. To identify ways of diagnosing PD at the earliest possible opportunity, the Michael J. Fox Foundation for Parkinson’s Research (MJFF) recently announced that it has partnered with Grifols, awarding the global healthcare company a US$21 million grant to identify biomarkers that could indicate the presence of the disease well before symptoms appear. “At MJFF, our mission is to accelerate breakthroughs for people living with Parkinson’s by funding diverse and innovative approaches,” said Shalini Padmanabhan, senior vice president of translational research at MJFF. “Identifying reliable biomarkers for Parkinson’s disease is essential to unlocking earlier diagnosis and more effective treatments. Grifols’ research on a plasma-based biomarker to detect PD as its earliest stage – before progression begins – aims to help us understand the biology of individuals who may be at risk and paves the way for transformative breakthroughs in care and prevention.” Grifols is well-placed to lead such an initiative, which it's dubbed ‘Chronos PD.’ Over nearly 15 years, the company has amassed a collection of more than 100 million plasma samples representing thousands of disease states – including Parkinson’s – connected to real-world health data. MJFF’s generous award will fund a pilot study led by Grifols’ subsidiary, Alkahest, to analyze plasma samples covering a period of up to 10 years to understand how distinct plasma proteins evolve over time in people with PD. Continue reading:

A recent study by Schindler et al., published in?Alzheimer’s & Dementia?and coordinated by the FNIH Consortium, evaluated the leading blood test candidates for Alzheimer's disease using plasma samples from the Alzheimer’s Disease Neuroimaging Initiative. - P-tau217 assays surpassed other biomarkers in accurately predicting both Aβ- and tau-PET positivity. Additionally, they demonstrated a stronger correlation with Aβ and tau PET burden. - Mass-spectrometry version of plasma p-tau217 (C2N PrecivityAD2) demonstrated the best performance. However, several immunoassay versions (Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix), which are easier to implement on a broader scale, gave similar results. - Plasma Aβ42/Aβ0, evaluated using both mass spectrometry and immunoassays, demonstrated significantly poorer performance compared to p-tau217 variants. - P-tau217 showed a stronger correlation with dementia symptoms compared to other biomarkers. However, its associations were not as strong as those between p-tau217 and the PET-based measures of Aβ and tau pathology. - Remarkably, cortical thickness showed a stronger correlation with??p-tau217 variants compared to plasma neurofilament light, which is frequently used to monitor neurodegeneration. - Measures of plasma GFAP, a biomarker associated with astrocytes and increasingly gaining attention, did not stand out for any of the clinically significant outcomes assessed. Taken together, these results further support the implementation of blood biomarkers to advance diagnosis, prognosis and treatment of patients with Alzheimer’s disease. Article title: "Head-to-head comparison of leading blood tests for Alzheimer's disease pathology" Journal: Alzheimer's & Dementia Link: https://lnkd.in/dEXPCaHy

ALZHEIMER'S DISEASE: BEYOND THE WELL-KNOWN MECHANISMS, FROM THE GLYMPHATIC TO THE LYMPHATIC PATHS, FROM THE GUT-BRAIN AXIS TO VASCULAR DYSFUNCTION, FROM METALS TO THE OLFACTORY PATHS AND ORAL HEALTH Alzheimer’s disease (AD) is the primary cause of dementia (60–80%) and one of the main neurodegenerative disorders in the elderly. Along with the expected increase in the elderly population from 703 million in 2015 to 1.5 billion by 2050, there is also an expected increase in dementia cases from 50 million to 152 million worldwide by?2050. Thus, Alzheimer’s disease constitutes a global health concern, resulting in a considerable economic burden. Until recently, the primary Food and Drug Administration (FDA)-approved treatment for Alzheimer’s disease focused only on symptoms and relied on acetylcholinesterase inhibitors such as rivastigmine, donepezil, and galantamine, in addition to memantine, an NMDA antagonist. To date, the FDA has approved three novel anti-Aβ pharmaceuticals that act as monoclonal antibodies: lecanemab, aducanumab (now discontinued), and donanemab, with the latter receiving approval in July 2024. As a result, these compounds represent the first FDA-approved disease-modifying therapy in AD, with many more molecules currently undergoing clinical trials. This open access review in?Int. J. Mol. Sci. emphasizes the underlying mechanisms of this condition. It explores not only wellstudied aspects, such as the accumulation of Aβ plaques and neurofibrillary tangles, but also novel areas, including glymphatic and lymphatic pathways, microbiota and the gut–brain axis, serotoninergic and autophagy alterations, vascular dysfunction, the metal hypothesis, the olfactory pathway, and oral health. Furthermore, the potential molecular targets arising from all these mechanisms have been reviewed, along with novel promising approaches such as nanoparticle-based therapy, neural stem cell transplantation, vaccines, and CRISPR-Cas9-mediated genome editing techniques. Taking into account the overlap of these various mechanisms, individual and combination therapies emerge as the future direction in the AD strategy. #AlzheimerDisease #GlymphaticPathway #LymphaticPathways M.G. Sighencea, R.S. Popescu, S.C.Trifu. From Fundamentals to Innovation in Alzheimer’s Disease: Molecular Findings and Revolutionary Therapies.? Int. J. Mol. Sci. 2024, 25, 12311.? https://lnkd.in/djZZr2Qe

?? Bridging Hematology and Cardio-Oncology – Join Us! ???? Don’t miss the opportunity to explore groundbreaking advancements in hematology and cardio-oncology at this specialized conference hosted by Researchers Fusion. This event is designed for experts, researchers, and clinicians dedicated to improving patient outcomes in these intertwined fields. ??? Date: [March 26-27/ 2025] ?? Location: [Baltimore, Maryland, USA] ?? Key Topics Include: ?? Advances in blood disorders and hematologic malignancies ?? Cardio-oncology: managing cardiovascular health in cancer patients ?? Latest therapeutic innovations and clinical trials ?? Strategies for integrated, patient-centered care ? Conference Highlights: ? Keynotes from leading hematologists and cardio-oncology specialists ? Hands-on workshops on diagnostic techniques and treatments ? Interactive panel discussions on cutting-edge research ? Global networking opportunities with peers and experts Whether you’re a healthcare provider, researcher, or policy advocate, this conference is your chance to stay ahead of the curve in these dynamic fields. ?? Learn More and Register Today: https://lnkd.in/gf2zj3Sa Let’s innovate and collaborate for a healthier future! ?????? #HematologyConference #CardioOncology #MedicalResearch #PatientCare #HealthcareInnovation

Congratulations to Anavex Life Sciences for having their phase 2b/3 placebo controlled Alzheimer’s results published in JPAD. Christopher Missling, PhD is expected at #JPM25 next week to present results of the lengthy open label extension, ATTENTION-AD. These open label results follow patient cognition and function longitudinally through 192 weeks. Paper: https://lnkd.in/eSNSWVbc I think these are the key points of the paper summarized succinctly: 1. ?Blarcamesine preserves cognition more than any available drug, and in the vast majority of the possible population (early disease stage w/S1R WT gene, 70-80%) 2. ?Blarcamesine likely gives innate resilience to neurodegeneration (brain shrinkage) as was evidenced by highly significant volumetric MRI. This is one of - if not the first drug - to demonstrate neurodegenerative resilience of this caliber [in pivotal trial] 3. ?Other markers of Alzheimer’s including amyloid were statistically significantly improved OR trended towards improvement. Note: tau trended towards improvement. There is growing evidence to support that tau is part of the brain’s immune response and not something that should be targeted directly. The trend in tau reduction may be a sign that the brain requires less immune response as upstream causation is ceased/lowered 4. ?Blarcamesine is an extremely attractive target because it’s orally administered and more efficacious FASTER than available therapeutics. No monoclonal antibody has demonstrated clinically meaningful cognitive preservation - but blarcamesine HAS. It’s also safer than monoclonal antibodies (aduhelm, Leqembi, Kisunla) as most safety concerns were mild and transient, and related to a quick uptitration which can easily be mitigated in real world 5. ?Blarcamesine could likely be administered as a monotherapy or combined with a monoclonal antibody for possible additive benefit 6. ?A rapid assay to confirm S1R gene status in the clinic would give clinicians the ability to educate individual patients to their likely response to drug. S1R mutation patients (20-30% of the population) still see benefit over placebo and would likely not be excluded from prescription. This doesn’t include off-label potential CNS-wide #precisionmedicine 7. ?Blarcamesine enhances autophagy (which has been proven in human cells with Blarcamesine AND other S1R agonists). Autophagy dysfunction is perhaps the earliest known sign of Alzheimer’s, beginning 1-2 decades before toxic amyloid build up. Hippocampus and amygdala atrophy are next in line pathophysiologically speaking - which were perserved significantly by drug 8. ?Known OLE abstracts support the notion that earlier treatment is correlated to better outcomes. More OLE data is expected to be unveiled at JPM25. EMA has accepted their application for centralized procedure (EU wide) and partnerships are likely to be heavily explored and possibly finalized in 2025 [my opinion] European Medicines Agency

???????????????? ???????????? ???? ?????????? ???? ?????? ?????????? ???????? ???? ????????! KYBORA's Jean Chatellier compiled a comprehensive list of the most promising clinical trials happening in the first half of the new year! Key trials are currently advancing in oncology, neuroscience, rare diseases, and gene therapies, showcasing the power precision medicine and innovative approaches can have when in unmet medical needs. Highlights include: ? ????????????????: BioNTech’s BNT327 aims to rival established therapies like Keytruda, while Summit Therapeutics’ Ivonescimab targets lung cancer with a first-in-class bispecific antibody. ? ?????????????????????????????????? ????????????????: Eisai and Biogen’s Clarity AD trials on lecanemab continue the push for Alzheimer’s treatments, alongside promising Parkinson’s and ALS studies. ? ???????? ????????????????: Beam Therapeutics’ BEACON trial uses base editing for sickle cell disease, while Rocket Pharmaceuticals tests gene therapies for Danon Disease. ? ?????????????????? ????????????????: Eli Lilly’s Orforglipron could revolutionize obesity treatment as an oral GLP-1 receptor agonist. ? ???????????????????? ????????????????: Moderna and Pfizer advance mRNA vaccines for flu, RSV, and pneumococcal diseases, while Sanaria’s PfSPZ-LARC2 malaria vaccine begins first-in-human trials. These innovative initiatives represent the future of healthcare, combining advanced technology with collaborative approaches to enhance patient outcomes. To read the full article, kindly click below. https://lnkd.in/dgK74Mpt #ClinicalTrials #MedicalInnovation #Oncology #GeneTherapy #Neuroscience #RareDiseases #PrecisionMedicine #KYBORA

A new study, developed and launched by the Foundation for the National Institutes of Health (FNIH)?Biomarkers Consortium, found some blood tests are accurate enough that they are suitable for clinical use and could replace spinal taps and brain scans in many patients with cognitive impairment. The study compared the accuracy of leading commercial blood tests in detecting amyloid plaques, a characteristic feature of Alzheimer’s. Some?blood tests?recently have been shown to identify the telltale brain changes of Alzheimer’s disease as accurately as established, more invasive methods, such as brain scans and cerebrospinal fluid tests. Yet, their widespread use in clinical practice has been limited by a lack of robust data validating their accuracy. The study results were presented today in an oral session at the?Alzheimer’s Association International Conference?(AAIC) in Philadelphia. The detailed study findings?are available?on the MedRxiv pre-print server. “The recent approvals of new anti-amyloid drugs—and the many treatments being studied in clinical trials—underscore the pressing need for more accessible, less invasive testing for early detection of Alzheimer’s,” said Julie Gerberding, MD, MPH, president and CEO of the FNIH. “This collaborative research effort has resulted in a rich dataset that is freely available to the scientific community and moves us closer to our goal—accelerating the development of Alzheimer’s diagnostic tools and therapeutic options for the millions of people who suffer from this disease.” The study confirmed that some blood tests have accuracy similar to established cerebrospinal fluid tests, which require a spinal tap, in determining the presence of amyloid plaques as measured by positron emission tomography (PET) scans. https://lnkd.in/eeP2s_2F

Please find new EFPIA report prepared by IQVIA brining a lot of insights about cancer, cardiovascular disease, dementia, COPD, rare disease or mental health new treatments.?? The report highlights several areas of innovation set to transform care for patients. Oncology remains the largest area for clinical research with 29% followed Neurology (7%).? Antimicrobial Resistance (AMR) contributing to 5M deaths globally with 52 trials initiated since 2021 (there is rise of AMR vaccines against Streptococcus Pneumoniae).?Additionally there are 97 assets novel anti-bacterial in pipeline (including 57 antibiotic). Non-communicable diseases are responsible for 41M deaths globally each year also can expect break thru treatments like for Epstein-Barr virus (EBV) which is implicated in the development of multiple sclerosis and some cancers. There are currently 3 prophylactic vaccines in early-stage development for EBV (first approvals expected in the 2030’s). mRNA vaccines development progress under 37 oncology trials have been initiated since 2022 with transformational personalized therapy for patients (like for colorectal cancer). Gene therapies where defective or missing genes are replaced shows that 175 clinical trials involving Adeno-Associated Viruses (AAV) based gene therapies have been initiated since 2022, with neurology and neuromuscular indications a focus?and several gene therapies for Duchenne Muscular Dystrophy (DMD).?? Major Depressive Disorder (MDD) a common mental health disorder with targeted population of 32M people in Europe have 248 trials initiated since 2019.?? Also, you can read about therapies in RNA technology for high lipoprotein, Stem cells for neurodegenerative disease, Next-gen obesity management medications, Anti-IL treatments for COPD and Novel therapies for major depressive disorder. Full report https://lnkd.in/guWG2m3n #EFPIA #IQVIA #clinicaltrials